SAB Biotherapeutics Holds Annual Stockholders Meeting

An update from SAB Biotherapeutics ( (SABS) ) is now available.

On July 17, 2025, SAB Biotherapeutics, Inc. held its Annual Meeting of Stockholders, where approximately 71.38% of the outstanding shares were represented. During the meeting, shareholders elected four Class I directors and ratified the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. These decisions are expected to impact the company’s governance and financial oversight positively.

The most recent analyst rating on (SABS) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on SAB Biotherapeutics stock, see the SABS Stock Forecast page.

Spark’s Take on SABS Stock

According to Spark, TipRanks’ AI Analyst, SABS is a Neutral.

SAB Biotherapeutics’ overall score is primarily impacted by its financial performance, which presents significant challenges due to declining revenues and persistent losses. Although technical analysis indicates positive momentum, the stock’s valuation is limited by a negative P/E ratio. The lack of recent earnings call data and corporate events leaves the financial performance and technical analysis as primary determinants of the score.

To see Spark’s full report on SABS stock, click here.

More about SAB Biotherapeutics

SAB Biotherapeutics, Inc. operates in the biotechnology industry, focusing on developing advanced immunotherapies. The company specializes in producing fully human polyclonal antibodies aimed at treating various diseases, with a particular emphasis on infectious diseases and immune system disorders.

Average Trading Volume: 48,911

Technical Sentiment Signal: Sell

Current Market Cap: $23.6M

See more insights into SABS stock on TipRanks’ Stock Analysis page.